Genomica Agreements with Glaxo Wellcome and Oxagen.BOULDER, Colo.--(BUSINESS WIRE)--July 16, 1998--Genomica Corp. announced today that it has entered into a license agreement with Glaxo Wellcome for Genomica's bioinformatics software Discovery Manager(TM) Product Suite. Separately, Genomica disclosed that it had previously signed a multiple year licensing agreement with Oxagen Ltd. for its Discovery Manager(TM) Product Suite. Oxagen is a genomics company, founded in 1997, as a spin-out from The Wellcome Trust The Wellcome Trust is a United Kingdom-based charity established in 1936 to administer the fortune of the American-born pharmaceutical magnate Sir Henry Wellcome. Its income was derived from what was originally called Burroughs Wellcome & Co, later renamed in the UK as the Centre for Human Genetics Human genetics A discipline concerned with genetically determined resemblances and differences among human beings. Technological advances in the visualization of human chromosomes have shown that abnormalities of chromosome number or structure are surprisingly (WTCHG WTCHG Wellcome Trust Centre for Human Genetics ). Terms of the two agreements were not disclosed. The full text of these announcements can be located on Genomica's website at www.genomica.com Genomica is a privately held company privately held company A firm whose shares are held within a relatively small circle of owners and are not traded publicly. headquartered in Boulder, Colorado. It is a bioinformatics company developing software and services to facilitate gene discovery and drug development. The company's bioinformatics tools combine clinical, epidemiology, genetic molecular biology molecular biology, scientific study of the molecular basis of life processes, including cellular respiration, excretion, and reproduction. The term molecular biology was coined in 1938 by Warren Weaver, then director of the natural sciences program at the Rockefeller and biochemistry into a single software package that enables scientiststo accelerate genetic discoveries and the development of molecular medicine. The company's software is intended to support a range of research activities to provide data that can be accessed and utilized by pharmaceutical and biotechnology companies. The company was established in 1996 by Thomas G. Marr, Ph.D., president and chief scientist of Genomica, to commercialize the tools that he and his team developed at Cold Spring Harbor Laboratory  The Cold Spring Harbor Laboratory in
New York New York, state, United StatesNew York, Middle Atlantic state of the United States. It is bordered by Vermont, Massachusetts, Connecticut, and the Atlantic Ocean (E), New Jersey and Pennsylvania (S), Lakes Erie and Ontario and the Canadian province of . Harris & Harris Group Inc. owns approximately 10.7 percent of the fully diluted equity of Genomica, which it valued on March 31, 1998, the most recent date on which it valued its equity investments, at its historic cost of approximately $1 million. Harris & Harris Group Inc. is a Business Development Co. with 10,641,400 common shares issued and outstanding. This press release may contain statements of a forward-looking nature relating to future events. Shareholders are cautioned that such statements are predictions and that actual events or results may differ significantly.
CONTACT: Harris & Harris Group, New York
Charles E. Harris, 212/332-3606
|
|
||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion